Also found in: Medical.
ABECBacute bacterial exacerbations of chronic bronchitis
References in periodicals archive ?
Once-daily FACTIVE tablets offer short-course dosing (five days for ABECB and seven days for CAP) with no dosing adjustment requirements in the elderly, individuals with liver impairment or individuals with mild-to-moderate renal impairment.
In these studies, FACTIVE tablets demonstrated excellent clinical response rates at test-of-cure visit for CAP and ABECB as good as comparators including clarithromycin, levofloxacin, amoxicillin/clavulanate, ceftriaxone and oral cefuroxime.
4) Treatment with appropriate antibiotics significantly decreases bacterial airway burden, suggesting that appropriate antibiotic use can reduce the symptoms of ABECB and decrease the risk of progression to a more severe infection.
10,12) High-risk ABECB patients commonly present with additional risk factors, such as poor underlying lung function ([FEV.
6,2) More alarmingly, in a recent clinical study of younger, low-risk patients with ABECB, 35% of S.
With unproven safety profiles, are new agents the best choice for ABECB therapy?
23) A recent study by Kahn et al evaluated patients with ABECB.
The Anthonisen classification system helps to establish a diagnosis of ABECB.
In ABECB, variables associated with treatment failure may be loosely categorized as those relating to clinical issues (eg, infection with a resistant pathogen) or those resulting in increased costs.
RELATED ARTICLE: Table 1: Criteria for Optimized Therapy of ABECB (6)
Atypical respiratory pathogens, most notably Chlamydophila (previously Chlamydia) pneumoniae, account for about 5% to 10% of organisms isolated from patients with ABECB.